The BCL2 family of proteins plays essential roles in controlling cell survival [26]; therefore, their altered expression and the appearance of BCL2 somatic mutations are associated with tumor progression, drug resistance, and disease recurrence [27–30]. This evidence concerns the gene BCL2 and neoplasm.